TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

NeoImmuneTech and Imugene Establish Strategic Research Collaboration to Enhance Cancer Treatment Advances

Tuesday, December 12, 2023

Imugene Ltd (ASX: IMU), a clinical-stage immuno-oncology company, and NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage biopharmaceutical company focusing on T-cell therapies, have announced a strategic collaboration. The collaboration aims to evaluate Imugene's allogeneic CAR T therapy, azer-cel, in combination with NeoImmuneTech's proprietary T cell amplifier, "Fc-fused recombinant human interleukin-7" (NT-I7), for the treatment of cancer.

Azer-cel, an allogeneic CD19 CAR T cell program, has demonstrated promising clinical activity and a potentially fast-tracked development strategy. It has shown efficacy with an acceptable safety profile in blood cancers such as lymphoma and leukemia.

NT-I7, also known as efineptakin alfa, is the only long-acting human IL-7 cytokine in clinical development. NT-I7 plays a critical role in T cell development and survival, enhancing the number, health, and functionality of cancer-fighting T cells. This immune system boost could offer improved benefits for cancer patients. NT-I7's stability, activity, and safety profiles make it an ideal partner for cell therapy drugs like azer-cel.

Leslie Chong, Managing Director & CEO of Imugene, expressed excitement about collaborating with NeoImmuneTech to enhance azer-cel's activity.

Dr. Se Hwan Yang, President and CEO of NeoImmuneTech, highlighted the encouraging results of NT-I7 in various immuno-oncology and infectious disease indications. The collaboration with Imugene, a leader in allogeneic cell therapy, is expected to expand the potential of NT-I7 and expedite its path to commercialization.

The strategic collaboration is effective immediately and will last for two years, exclusively within the United States. Imugene will fund its portion through existing planned research activities, with no additional funding required for the initial collaboration. Both parties retain full intellectual property rights to their background technologies. In the event of new intellectual property arising from the collaboration, the parties will engage in good faith discussions regarding filing, prosecution, and other matters related to such joint collaboration technology.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit